Verici Dx plc (LON:VRCI – Get Free Report) fell 8.7% during trading on Monday . The company traded as low as GBX 2.50 ($0.03) and last traded at GBX 2.74 ($0.03). 82,494 shares traded hands during trading, a decline of 75% from the average session volume of 335,945 shares. The stock had previously closed at GBX 3 ($0.04).
Verici Dx Price Performance
The company has a current ratio of 4.54, a quick ratio of 8.49 and a debt-to-equity ratio of 4.65. The stock has a 50 day simple moving average of GBX 4.40 and a 200-day simple moving average of GBX 6.13. The firm has a market cap of £6.64 million, a PE ratio of -150.00 and a beta of 1.59.
Verici Dx Company Profile
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
See Also
- Five stocks we like better than Verici Dx
- What is a Stock Market Index and How Do You Use Them?
- 3 Green Hydrogen Stocks That May Survive the Trump Chopping Block
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Palo Alto Networks: A Pre-Split Investment Opportunity?
- 5 Top Rated Dividend Stocks to Consider
- 3 Growth Stocks That Won’t Slow Down in 2025
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
